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Abstract 
Nature is considered a prolific source of diverse biologically active chemotypes. While 
most reviews have focused on the characteristics of the chemical backbones of natural 
products (NPs), few have tried to provide an overview of their origins (the living organisms 
in which they are produced), chemical classes, and biological activities. This review 
discusses the current knowledge on NP diversity by focusing on the Dictionary of Natural 
Products® (DNP). We datamined the 300,000 NPs covered by the DNP to reveal 
relevant, albeit dormant, knowledge about NP diversity.%This holistic picture of NPs allows 
us to discuss the most abundant biological sources of NPs investigated in relation to their 
chemical features and biological activities. In a nutshell, a large part of NPs originated 
from plants (67%), especially from the Compositae and Leguminosae families. Among all 
kingdoms, NPs isolated from Streptomyces spp. were largely represented, while 
terpenoids and alkaloids were the two most represented chemical classes. Out of all NPs 
documented, only 3,882 were reported to be bioactive (1,163 from plants and 1,006 from 
bacteria), with antibacterial, antibiotics, and antineoplastic agents being the most frequent 
therapeutic classes. In this paper, we also address the advantages and limitations of NP 
research from a pharmaceutical industry perspective. This work will provide useful 
insights and guidance to researchers involved in drug discovery from NPs. 
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Introduction 
 Natural products (NPs) have been used in various branches of traditional 
medicine for millennia. The oldest written records of NPs as medicine date as far back as 
4,600 years ago (Dias et al. 2012; Cragg and Newman 2013). Due to their chemical 
diversity, their structural complexity, and their biological selectivity, NPs are considered 
to be a great source of inspiration for the development of potential novel drugs (Clardy 
and Walsh 2004; Atanasov et al. 2015). From 1981 to 2014, about 51% of all new 
approved drugs were of (or derived from) natural sources, amounting to 65% of all 
antibacterial compounds and 73% of all anticancer compounds (Newman and Cragg 
2016). It is expected that newly discovered natural compounds will continue to play an 
important role in drug discovery (Baker et al. 2007; Harvey et al. 2015). 
Natural product databases have been developed to assist with in silico and in vitro 
screening in drug discovery. A number of NP libraries are already available and include 
general databases such as SuperNatural 2 (≈ 326,000 NP) (Banerjee et al. 2015) and the 
Universal Natural Products Database (≈ 229,000 compounds) (Chen et al. 2017b). 
Specialized databases have also been designed, including those focusing on indigenous 
medicines such as AfroDb for African medicinal plants (Ntie-Kang et al. 2013), NuBBE 
for Brazilian biodiversity (Valli et al. 2013), iSMART, and TCMID for traditional Chinese 
medicine (Chang et al. 2011; Xue et al. 2013); and those focusing on specific types of 
NPs such as HIT for herbal ingredients and their targets (Ye et al. 2011), SuperToxic for 
toxic compounds (Schmidt et al. 2009), NPACT for anticancer NPs (Mangal et al. 2013), 
and MarinLit for marine NPs (Chen et al. 2017b).  
The Dictionary of Natural Products® (CRC Press, v. 27.1) (DNP) is a compilation 
of all known compounds derived from natural sources and can be considered as one of 
the most comprehensive libraries of NPs available to date (Quinn et al. 2008; Gaudêncio 
and Pereira 2015; Chen et al. 2017b). The latest version of the DNP (v. 27.1, at the time 
of writing) provides data for nearly 300,000 natural compounds, and it contains 
information on the chemical, physical, and biological properties of compounds; along with 
their systematic and common names, literature references, molecular structures, and 
natural sources for purification (including family, genus, and species).%Due to its rich 
content, the DNP can be considered as a body of knowledge for NPs and can be used to 
guide investigations in NP-based drug discovery. 
Since its development, several studies have used and explored the content of the 
DNP. One of the first comprehensive reports was published by Henkel et al. (1999) who 
investigated the differences between the structural properties of NPs found in the DNP 
and those of synthetic substances; then Whittle et al. (2003) evaluated various similarity 
measures for screening molecular fingerprints from the DNP; later Koch et al. (2005) 
introduced a structural classification of NPs to chart biologically relevant chemical space. 
With the same objective, Rosén et al. (2009) compared the chemical space of bioactive 
medicinal chemistry compounds from the WOMBAT database to that of products from the 
DNP; in 2008, Quinn et al. (2008)%used the DNP to develop a library of NPs that exhibit 
drug-like properties; also Kong et al. (2011) performed a historical analysis on the 
structural novelty of products from the DNP; more recently, Pascolutti et al. (2015) 
identified fragment-sized NPs from the DNP to capture the structural diversity of nature. 
These studies mainly focused on the characteristics of the chemical backbones of the NP 
contained in this database, but none of them strove to provide an overview of their origins 
(the living organisms in which they are produced), chemical classes, and biological 
activities. To the best of our knowledge, only Bérdy (2005) summarized compounds 
isolated from natural sources, but his review was limited to bioactive compounds from 
microbial sources. 
In this review, we unveil the current knowledge on NP diversity based on a 
descriptive study of the DNP (v. 27.1). This includes a characterization of all compounds 
(primary and secondary metabolites) from the DNP in relation to their natural sources (all 
types of organisms are considered), chemical classes, and biological activities (NPs 
without bioactivities are also reviewed). Natural products with biological activities 
annotated in the DNP are defined as “compounds with established activity and being used 
as drugs or under investigation for drug use” (Taylor & Francis group, pers. comm.). 
Finally, we also discuss the potential application of NPs in the pharmaceutical industry. 
Defining the number of NPs already identified 
A key issue in NP research is the estimation of the number of known NPs. First, 
Bérdy (2005) estimated the approximate number of known NPs to be close to one million. 
Later, the same author proposed that the number of published natural compounds was 
actually between 300,000 and 600,000 (Bérdy 2012). However, little information was 
provided on the methodology used to infer these figures. Other authors based their 
estimations on the number of compounds tabulated in the NP databases (Blunt et al. 
2012). At present, in the general NP databases, the number of compounds described 
amounts to 326,000 NPs in Super Natural 2, 293,798 NPs in the DNP, 283,000 NPs in 
the Chemical Abstract Services (CAS) registry, and 220,000 NPs in Reaxys (Gaudêncio 
and Pereira 2015; Chen et al. 2017b). By comparing the number of unique NPs from a 
wide range of commercial and freely available virtual databases, Chen et al. (2017b) 
estimated a figure close to 250,000 NPs. Since the authors did not include SuperNatural%2 
and Reaxys in their analysis, the number of known NPs is likely to be higher. Furthermore, 
the number of NPs could even be larger if we consider the molecular fossils produced 
from natural products (Falk and Wolkenstein 2017). 
In the DNP, out of the 194,977 NPs with information on organism classification, 
most of the NPs were from the Plantae kingdom (133,881 NPs, 67.3%), while Animalia 
ranked second (25,064 NPs, 12.6%), followed by Fungi (19,869 NPs, 9.99%) and 
Eubacteria (17,531, 8.81%) (Figure 1a). Regarding the chemistry of NPs, terpenoids and 
alkaloids groups were the two most represented chemical classes in these four kingdoms, 
and they represented more than half of all compounds isolated from the Plantae kingdom 
(Figure 1b). In contrast, some chemical classes did not have a cross distribution in the 
different kingdoms of life. This is the case of steroid NPs which were seldomly 
represented in the Bacteria kingdom. Likewise, flavonoids and lignans were almost 
exclusively found in Plantae kingdom, while polyketides were mainly found in Bacteria, 
Fungi, and Protista kingdoms, which emphasize two distinct crossroads among the 
acetate pathway. 
In the following sections, we provide a detailed analysis of the chemodiversity found in 
the most represented families and species of each kingdom with a special focus on their 
pharmacologically active compounds. 
Figure 1. Overview of the Dictionary of Natural Products database (a) Distribution of 
natural products per kingdom of life; (b) Distribution of the main chemical classes of 
natural products in each kingdom of life. 
8%
NPs from the Plantae kingdom 
A large percentage of the NPs (67.3%) recorded in the DNP are from the Plantae 
kingdom. This is consistent with Bérdy (2012) who estimated that approximately 70% of 
NP are of plant origin. From a historical perspective, this is not surprising since medicinal 
herbs were the first natural substances to be studied. It started with the isolation of 
morphine (alkaloid) in 1817 by a German pharmacist named Friedrich Sertuerner 
(Sertuerner, 1817). It gained momentum during the nineteenth century with the discovery 
of a wide range of natural compounds of plant origin (e.g., aspirin, atropine, caffeine, 
cocaine, colchicine, quinine, nicotine, and strychnine). Then, the discovery of penicillin in 
1928 by Alexander Fleming and its purification by Howard Florey in 1938 led to an era of 
natural products discovery from microbial sources (David et al. 2015; Atanasov et al. 
2015; Bernardini et al. 2017).  
One of the distinctive features of the plant compounds compiled in the DNP is the 
high proportion of terpenoids, which are especially pervasive in the Gymnosperms group 
(57% of the total NPs) and in the Dicotyledons group (40%) (Figure 1b). Terpenoids are 
known as the largest and the most diverse class of NPs, and they play various roles in 
plant development and growth, as well as in communication and defence (Langenheim 
1994; Gershenzon and Dudareva 2007). In the DNP, one third of terpenoid NPs have 
antineoplastic-related activities including, for instance (Huang et al. 2012):  
• Limonene, a monoterpene from Citrus limon (L.)  Osbeck.
• Tanshinone IIA, a diterpene from Salvia miltiorrhiza Bunge.
• Celastrol, a triterpene from Tripterygium wilfordii Hook. f.
• Lycopene, a tetraterpene from Lycopersicon esculentum Mill.
76%
Most of the NPs isolated from the Plantae kingdom are from the dicotyledons group 
(Angiosperms clade) (83.7%), followed by the monocotyledons group (8.1%), and the 
Gymnosperms clade (3%). Liverworts, ferns, fern allies, and mosses represent only a 
small part of the NP recorded (3.2%), just as rhodophyta and chlorophytes groups (2%). 
Furthermore, three botanical families (Compositae, Leguminosae, and Labiatae) host 
about one quarter of the total compounds from the Plantae kingdom (Figure 2). With over 
32,700 species recorded, Compositae (also known as Asteraceae) is the largest family 
of flowering plants worldwide, while Leguminosae (or Fabaceae) is the third-largest with 
more than 20,800 species (Roskov et al. 2018). 
Figure 2. The top 15 botanical families containing natural products and the distribution of 
the different chemical classes. 
In the Compositae family, the Artemisia genus, one of the largest genera in this 
family (≈ 500 species), was the most represented in the DNP (1,299 NP) (Suppl. Mat. 
S1A). The antimalarial compound, artemisinin, isolated from the traditional Chinese 
medicinal herb Artemisia annua L. in 1971 led to the development of various derivatives 
(e.g., artemether and sodium artesunate), and it has also attracted renewed interest into 
sesquiterpenes which are well represented in this genus (Kayser et al. 2003; Atanasov et 
al. 2015). For example, arglabin isolated from A. glabella Kar. & Kir. is used in Kazakhstan 
for cancer chemotherapy, and santonin produced by A. cina Berg ex Poljakov was widely 
used in the past as an anthelminthic agent (Ivanescu et al. 2015). 
According to the DNP, about half of the compounds found in the Leguminosae 
family are flavonoids. Indeed, a wide range of flavonoids are found in this botanical family 
including quercetin, kaempferol, and their derivatives (Wink 2013). Some of which are 
currently available or under investigation as drugs, such as genistein from Glycine max 
(L.) Merr. which is in clinical trials for use as an angiogenesis inhibitor (Veitch 2010; Russo 
et al. 2016). Other compounds isolated from the Leguminosae family that are of major 
importance in human health include the oleanane triterpenoids from Glycyrrhiza glabra L. 
(e.g., glycyrrhizin used as anti-inflammatory agent), polycyclic aromatic NP from Cassia 
angustifolia M.Vahl (i.e., sennosides used as laxatives), and cyclotryptamine alkaloids 
from Physostigma venenosum Balf. (i.e., physostigmine used to treat neurological 
diseases). Altogether, the Leguminosae family is known as the most drug-prolific 
botanical family with 44 drugs either approved or in clinical trials in 2011 (Zhu et al. 2011). 
The Labiatae family (or Lamiaceae) is the third largest botanical group, and 
according to the DNP a large number of the compounds (71%) isolated from this family 
are terpenoids. These results could be explained by the numerous reports on volatile oils 
(mainly monoterpenes and sesquiterpenes) found in genera of economic importance 
(e.g., Lavandula, Mentha and Thymus) (Wu et al. 2012). Salvia species account for 
almost 20% of the overall NPs isolated from Labiatae, with Salvia miltiorrhiza Bunge being 
the most represented. S. miltiorrhiza (Danshen in Chinese) is a very popular traditional 
Chinese herb used to treat several conditions including cardiovascular, cerebrovascular, 
and hyperlipidaemia diseases (Wu et al. 2012). Lipophilic diterpenoids (i.e., tanshinones) 
and hydrophilic phenolic acids (i.e., salvianolic acids) are the main bioactive constituents 
of this species. These compounds have been shown to possess various pharmacological 
effects ranging from anticancer properties to effects on cardiovascular diseases (Su et al. 
2015). More than thirty clinical trials of S. miltiorrhiza and its tanshinones have been 
undertaken to justify its use in stroke patients, angina, and other ischemic conditions 
(Adams et al. 2006; Tan et al. 2018). Moreover, Dantonic, a Chinese botanical drug 
containing S. miltiorrhiza extracts, has gone through Phase III clinical trials (completed in 
2016) by the U.S. Food and Drug Administration (FDA) for the treatment of angina 
pectoris and cardiovascular diseases (Chao et al. 2017).  
Of the most cited genera in the DNP, the Euphorbia genus ranks first in the Plantae 
kingdom and fourth amongst all kingdoms. With about 2,160 known species, Euphorbia 
is the largest genus in the Euphorbiaceae family and the third-largest amongst the 
flowering plants (Jassbi 2006; Ernst et al. 2015). In the DNP, approximately two thirds of 
the total NPs (1,008 compounds) isolated from this genus are diterpenoids. The 
diterpenoids are the most studied chemical class from Euphorbia species, especially the 
polycyclic diterpenoids (e.g., jatrophane, ingenane, tigliane, and lathyrane) (Shi et al. 
2008). Indeed, these compounds are taxonomic markers of the Euphorbiaceae family 
(they occur only in Thymelaeaceae and Euphorbiaceae families), and are lead 
compounds in drug discovery from NPs (Vasas and Hohmann 2014). One diterpenoid 
compound (i.e., ingenol mebutate isolated from E. peplus) was approved by the FDA and 
the European Medicines Agency in 2012 for the treatment of actinic keratosis, and it is 
currently used in clinical practice (Cantisani et al. 2013).  
Interestingly, Tripterygium wilfordii Hook. f. (Celastraceae) was the Plantae 
species that exhibited the highest number of NPs in the DNP (315) (Table 1). This liana 
has been used in traditional Chinese medicine for more than 2,000 years for the treatment 
of arthritis, muscle, and skeletal injury, as well as skin diseases (Chen 2001). In the 
1960s, formulations of T. wilfordii began to be used in Chinese allopathic medicine to 
treat patients with inflammatory lesions caused by leprosy, and patients with rheumatoid 
arthritis (Tao and Lipsky 2000). Since then, numerous clinical trials have been conducted 
for the treatment of inflammatory diseases, and over 300 compounds have been identified 
from this plant,% many of which displaying immunosuppressive and anti-inflammatory 
effects (Brinker et al. 2007). Its most abundant metabolites are diterpenoids including 
triptolide, tripdiolide, and triptonide (Goldbach-Mansky 2009). Triptolide analogues are 
currently in Phase II clinical trials for the treatment of rheumatoid arthritis and cancer 
(Chen et al. 2018). 

NPs from the Bacteria kingdom 
According to the DNP, the number of NP from the Bacteria kingdom is less than 
that from the other kingdoms of life (only 9% of the total compounds from living 
organisms). However, the percentage of bioactive compounds from the Bacteria kingdom 
is three to five times higher than that from the other kingdoms of life (Suppl. Mat. S1B). 
Bérdy (2012) estimated that approximately 8% of NPs were from bacterial origin 
(actinobacteria and unicellular bacteria), but 47% of these compounds exhibited some 
kind of biological activity. Interestingly, the latter figure was lower in plants (7%) and in 
animal-derived compounds (3%).  
Bioactive compounds from bacterial origin mainly display antibiotic and 
antibacterial properties (67% of bioactive NPs from the Bacteria kingdom in the DNP) 
(Figure 3). Regarding the number of FDA approved drugs from natural sources, Patridge 
et al. (2016) reported that 51% of antibacterial agents were from bacterial origin.  
Many NPs from bacteria belong to the amino acid and peptide class (Figure 1). In 
the DNP, 27% of NPs from bacterial origin were amino acids and peptides, and cyclic- 
oligo- and polypeptides were the main represented chemical subclass with 1,147 NPs. 
Moreover, the amino acid and peptide group (236 NPs) and the polyketide group (248 
NPs) combined amount to approximately half of the bioactive NPs from bacterial sources. 
Figure 3. The top 10 activities of natural products and their distribution by kingdom of 
life. 
Among all living organisms, the Streptomycetaceae family and Streptomyces 
species rank top as producers of NPs (7,951 NPs in total from Streptomyces) (Table 2). 
Bérdy (2005) estimated that 34% of metabolites from microbial sources were from this 
genus. In our study, we found that this number is even higher and reaches 45%. Indeed, 
with the discovery of streptothricin in 1942 and streptomycin in 1943 at the beginning of 
the antibiotic era, attention turned to Streptomyces species. Pharmaceutical companies 
engaged in large efforts to discover NPs by developing research programs based on 
microbial fermentation, and by focusing mainly on antibacterial and antifungal targets 
(Clardy et al. 2006; Baker et al. 2007; Katz and Baltz 2016). In the 1950s and 1960s, 
about 70-80% of antibiotics were discovered from Streptomyces species and this 
percentage was still high at the beginning of the 1990s (≈ 40-50%) (Bérdy 2005). Several 
important compounds belonging to various antibiotic classes were discovered from 
Streptomyces species including β-lactams (cephamycin and carbapenems); 
aminoglycosides (neomycin and kanamycin); macrolides (tylosin and spiramycin); 
peptides (actinomycin); polyenes (candicidin, amphotericin B and nystatin); and 
tetracyclines (tetracycline, chlortetracycline and oxytetracycline) (Katz and Baltz 2016). 
Besides the discovery of antibiotics, a wide range of compounds related to various 
therapeutic classes have been isolated from this genus. Let us mention anthelminthic and 
antiparasitic drugs (e.g., ivermectins), anti-tumour products (e.g., bleomycin and 
doxorubicin), anti-obesity agents (e.g., lipstatin), immunosuppressive agents (e.g., 
rapamycin) and herbicides (e.g., bialaphos). Altogether, Watve et al. (2001) estimated 
that this genus is capable of producing approximately 100,000 antimicrobial compounds, 
of which only 1-3% have been discovered so far. 

More generally, microbial organisms from the Actinomycetales order represent the 
largest group of bioactive bacterial compounds. According to the DNP 9,261 compounds 
have been isolated from these species, including the largest genus Streptomyces, but 
also rare actinomycetes such as Micromonospora (436 total NPs and 84 bioactive NPs), 
Nocardia (312 and 32) and Actinomadura (267 and 27) species. The discovery of rare 
actinomycetes increased significantly between the 1970s and the 1990s, and during this 
period about 30% of new antibiotics stemmed from these species (Bérdy 2005). Besides 
the fact that they are difficult to isolate and cultivate, one of the distinctive features of the 
rare actinomycetes is their production of diverse, unique, and complex compounds with 
excellent antibacterial potency and usually low toxicity (Lazzarini et al. 2000; Kurtböke 
2012). Glycopeptide and orthosomycin antibiotics are produced almost exclusively by 
rare actinomycetales (Bérdy 2005). Some of the successful antibacterial agents currently 
on the market include gentamicin isolated from Micromonospora purpurea, erythromycin 
produced by Saccharopolyspora erythraea, rifamycins by Amycolatopsis rifamycinica and 
vancomycin by Amycolatopsis orientalis (Tiwari and Gupta 2012). Moreover, the rare 
actinomycetes are highly drug-prolific, with the Pseudonocardiaceae family (including 
Amycolatopsis and Saccharopolyspora species) being the most productive with 76 
approved drugs in 2011 (Zhu et al. 2011). Nowadays, rare actinomycetes can be isolated 
from diverse environments (i.e., marine sources, soil samples, plant materials, and 
extreme environments) and intensively studied in antibiotic discovery programs (Jose and 
Jebakumar 2013; Dhakal et al. 2017). 
Finally, other eubacteriales species including Pseudomonas, Bacillus and 
Escherichia species are among the highest producers of NPs. Bérdy (2005) already 
stressed the importance of the Bacillus and Pseudomonas species as the most prolific 
producers of bioactive metabolites from the unicellular bacteria group. Due to their 
ubiquity in the environment (i.e., soil, water, plants, and animals), Pseudomonas species 
are known to synthetize a wide range of metabolites (Gross and Loper 2009). In particular, 
Pseudomonas is one of the most common genera associated with plants as it contains 
epiphytic, endophytic, and pathogenic species (Strobel et al. 2004). They have been 
found to produce phytotoxic compounds as well as antimicrobial agents involved in the 
biocontrol of plant pathogens (Haas and Défago 2005). For example, P. viridiflava, 
associated with the leaves of grass species, produces ecomycins — a family of 
lipopeptides active against Cryptococcus neoformans and Candida albicans (Miller et al. 
1998). Bacillus species produce mainly peptide antibiotics such as lantibiotics which 
contain the uncommon thioether amino acids lanthionine and ß-methyllanthionine (Stein 
2005). Various lantibiotics have been isolated from Bacillus species including subtilin from 
B. subtilis, haloduracin from B. halodurans, lichenicidin from B. licheniformis, and
cerecidins from B. cereus (Lawton et al. 2007; Dischinger et al. 2009; Wang et al. 2014). 
Since the 1970s, Escherichia coli have been widely used as a model for the development 
of DNA recombinant technology (Katz and Baltz 2016). Nowadays, it is the most 
employed host for the expression of drug candidates and small molecules (Atanasov et 
al. 2015). Thus, metabolites from E. coli have been widely studied and this may explain 
the high number of NPs from this species in the DNP (Reed and Palsson 2003). 
NPs from the Fungi kingdom 
In the DNP, approximately 20,000 compounds were reported to belong to the 
Fungi kingdom, and two divisions (Ascomycota and Basidiomycota) account for almost 
90% of the total fungal products.%The Fungi kingdom is thought to contain the largest 
number of microbial metabolites. 
Compared to the other kingdoms, fungal products are structurally less complex 
and have smaller molecular weights (Bérdy 2005). A wide range of chemical classes are 
represented among fungi, including terpenoids (e.g., paclitaxel from Taxomyces), 
alkaloids (e.g., ergot alkaloids from Claviceps), simple aromatic NPs (e.g., griseofulvin 
from Penicillium), amino acids and peptides (e.g., echinocandins from Aspergillus and β-
lactams from Penicillium), benzofuranoids (e.g., mycophenolic acid from Penicillium), 
carbohydrate NPs (e.g., ß-glucans from basidiomycetes), polycyclic aromatic NPs (e.g., 
parietin from lichens), and polyketides (e.g., aflatoxins and lovastatin from Aspergillus) 
(Figure 4) (Goyal et al. 2016). This plethora of diverse fungal metabolites is associated 
with various biological activities ranging from pharmacological agents to mycotoxins 
(Peláez 2005; Goyal et al. 2016).  
Figure 4. Structures of biologically active compounds of plant, bacterial, fungal and 
animal origin. 
With more than 13,000 compounds, the Ascomycota division is the largest 
producer of NPs in the Fungi kingdom (Suppl. Mat. S1C). This group is also the largest 
phylum of Fungi (64,000 known species) and one of the most ubiquitous phyla of 
eukaryotes (Schoch et al. 2009). It comprises filamentous fungi (e.g., Aspergillus and 
Penicillium) but also yeasts (e.g., Saccharomyces cerevisiae), endophytic species (e.g., 
Alternaria, Phoma, Stachybotrys and Trichoderma), and lichen-forming fungi 
representing 40% of all ascomycetes (e.g., Cladonia, Lecanora and Parmelia) (Bérdy 
2005; Blackwell 2011).  
One of the milestones in the history of NPs from ascomycetes is the discovery of 
penicillin from the fungus Penicillium chrysogenum in 1928 by Alexander Fleming. This 
discovery led to the production and commercialization of synthetic penicillins in the early 
1940s which saved a huge number of lives during WWII and ushered in the “Golden Age 
of Antibiotics” from the 1940s to the 1970s (Cragg et al. 2014; Bernardini et al. 2017). 
Besides the important discovery of β-lactams from Penicillium species, other NPs with 
pharmaceutical activities have also been isolated from this genus including mycophenolic 
acid, an immunosuppressant agent produced by P. brevicompactum; griseofulvin, an 
antifungal agent isolated from P. griseofulvum, and compactins known for their 
cholesterol-lowering activities produced by P. brevicompactum and P. citrinum (Frisvad 
et al. 2004; Chakravarti and Sahai 2004). 
While the Penicillium genus is the second-largest producer of NPs in the 
Ascomycota division, Aspergillus is the most represented genus with A. terreus being the 
most prolific species from this genus in the DNP. Indeed, Aspergillus is renowned for its 
medical, pathogenic, and industrial importance (Sanchez et al. 2012). As an example, 
A. terreus is a significant cause of aspergillosis, but it is also the main source of lovastatin,
the first commercially marketed statin which was approved by the FDA in 1987 for the 
treatment of hypercholesterolemia (Demain and Sanchez 2009). Nowadays, synthetic 
derivatives of lovastatin are among the world’s most sold drugs (Katz and Baltz 2016). 
Another example is that of A. nidulans, a model organism widely used to study genetics 
and cell biology, but it is also the main producer of echinocandins, a family of lipopeptides 
used in the treatment of candidiasis (Denning 2003). The first licensed semisynthetic 
echinocandin derivatives were caspofungin, micafungin and anidulafungin since 2001 
(Butler 2008). Of all Aspergillus species, A. fumigatus is the primary causative agent of 
human infection, and gliotoxin is the main mycotoxin involved in mycosis (Dagenais and 
Keller 2009). A. fumigatus also produces fumagillin, first isolated in 1949 and used in the 
treatment of microsporidiosis (Mishra and Tiwari 2011). Finally, Aspergillus species 
(especially A. flavus and A. parasiticus) are also a unique source of aflatoxins, a major 
class of mycotoxins that have been described as human carcinogens and implicated in 
hepatocellular carcinoma (Henry et al. 2002; Mishra and Das 2003).  
Endophytic fungi are also well represented in the DNP with Fusarium (i.e., F. 
oxysporum and F. solani), Trichoderma (i.e., T. harzianum and T. viride), Alternaria (i.e., 
A. alternata), and Chaetomium genera (i.e., C. globosum) ranking 3rd, 4th, 5th and 6th
respectively in terms of NPs per genus. Endophytic fungi are defined by their occurrence 
within internal tissues of plants without causing any immediate overtly negative effects 
(Stone et al. 2000). They represent a polyphyletic group of ascomycetous fungi and are 
found in various plants including liverworts, mosses, ferns, and seed plants (Aly et al. 
2010). Interest in endophytic strains began with the detection of paclitaxel (an anti-tumour 
agent originally isolated from the plant species Taxus brevifolia) from the endophytic 
fungus Taxomyces andreanae (Stierle et al. 1993). This discovery highlighted the 
potential of endophytic fungi as alternative sources of plant secondary metabolites, and 
led to a shift in the discovery of new compounds from fungal sources in the early 1990s 
(Bérdy 2005). In the last decade, about half of the newly discovered fungal metabolites 
(approximately 5,000 compounds) were from endophytic fungi (Aly et al. 2010; Bérdy 
2012). This includes various compounds belonging to different chemical classes such as 
aldehydes (e.g., chaetopyranin from Chaetomium globosum), alkaloids (e.g., 
camptothecin from Fusarium solani), lignans (e.g., podophyllotoxin from Fusarium 
oxysporum), peptides (e.g., beauvericin from Fusarium oxysporum), polyketides (e.g., 
alternariol from Alternaria species), steroids (e.g., wortmannins from Talaromyces 
wortmannii), and terpenoids (e.g., pestalotiopsins from Pestalotiopsis spp.) (Tan and Zou 
2001; Kharwar et al. 2011; Gao et al. 2018). Moreover, in a literature review of 135 
metabolites isolated from endophytic fungi, it was shown that the proportion of novel 
chemical structures produced by endophytes is significantly higher (51%) than that 
produced by fungi isolated from soil (38%), thus confirming that endophytes are a good 
source of bioactive metabolites (Schulz et al. 2002). 
In addition to ascomycetes, basidiomycetes are also of great importance since 
amongst the fungi kingdom they are the second-largest producer of NPs in the DNP 
(4,820 NP). This group is also the second-largest phylum of fungi (22,000 known 
species), and it includes most of the macroscopic fungi (Bills et al. 2005). One of the main 
features of basidiomycetes is the presence of compounds with high molecular weight 
such as polysaccharides, proteins, and lipids, as well as low molecular weight metabolites 
including alkaloids, peptides, polyketides, steroids, and terpenoids (De Silva et al. 2013). 
Polysaccharides have been widely studied, and in particular the study of ß-glucans has 
led to the development of anticancer drugs used in Asia such as lentinan from Lentinula 
edodes, schizophyllan from Schizophyllum commune and two specific proteoglycans 
(polysaccharide krestin [PSK] and polysaccharopeptide [PSP]) from Trametes versicolor 
(Lindequist et al. 2005). Secondary metabolites produced by basidiomycetes have also 
been investigated and have proved to be a source of bioactive compounds with, e.g., 
strobilurins isolated from Strobilurus tenacellus used as fungicides; pleuromutilins 
produced by Pleurotus mutilus and its semisynthetic derivative (retapamulin) used in the 
topical treatment of impetigo; and illudins isolated from Omphalotus spp. and their 
analogue (irofulven) currently under investigation as anticancer drugs (Stadler and 
Hoffmeister 2015). 
Ganoderma species account for almost 10% of the total compounds isolated from 
basidiomycetes, and in the DNP half of these compounds are from G. lucidum. Also 
known as “Lingzhi”, this species has been widely used in traditional Chinese medicine to 
promote good health and to treat many diseases including allergy, arthritis, cancer, 
hypertension, and inflammation (Paterson 2006). Polysaccharides (e.g., ß-glucans) and 
triterpenoids (e.g., ganoderic acids) are the two major groups of compounds that exhibit 
pharmacological effects, especially anticancer and immunomodulatory activities (Yuen 
and Gohel 2005). Extracts of G. lucidum, and the medicinal peptide, Ling Zhi-8, are 
currently under investigation for use as chemopreventive and adjuvant agents in the 
treatment of cancer (Cheng and Sliva 2015; Chen et al. 2017a). 
NPs from the Animalia kingdom 
Of all the kingdoms Animalia ranks as the second-largest producer of NPs in the 
DNP. More than 25,000 NPs have been identified from animal sources, and 
approximately half of these compounds belong to the terpenoid and alkaloid groups.  
In the DNP, one quarter of the bioactive NPs from animal sources were isolated 
from their venoms and toxins, among which amino acid and peptide NPs are highly 
represented (97%) (Figure 5). The best-known example of a successful venom-based 
drug is that of the angiotensin-converting enzyme (ACE) inhibitors which act as 
antihypertensive agents. A venom peptide (teprotide) was isolated from the snake 
Bothrops jararaca in the 1960s and led to the development of ACE inhibitors (i.e., 
captopril, enalapril and lisinopril) which are currently among the top best-selling drugs in 
the world (Lewis and Garcia 2003; Antunes et al. 2016). Other venomous animals have 
also been investigated for their pharmaceutical potential such as the Gila monster 
Heloderma suspectum which afforded exendin-4, an antidiabetic agent approved by the 
FDA in 2005; the medicinal leech Hirudo medicinalis which led to the development of 
bivalirudin, a synthetic analog of hirudin with anticoagulant activity approved by the FDA 
in 2000; and the cone snail Conus magus which produces ω-conotoxins, the synthetic 
form ziconotide was approved in 2004 for the treatment of refractory neuropathic pain 
(King 2011; Zambelli et al. 2016).%Interestingly, among all of the kingdoms Conus is one 
of the genera that produces the largest number of bioactive compounds, since more than 
100 bioactive NPs (accounting for more than 70% of the total NPs from this genus) have 
been recorded in the DNP. This high number of diverse pharmacologically active 
compounds results from the high rate of hypermutations as well as the remarkable 
number of post-translational modifications in this genus which allow little overlap in 
conopeptides between Conus species (Buczek et al. 2005). To date, it is estimated that 
the number of conopeptides per species might exceed 1,000, and that a total of 35,000 
compounds could be available from the 700 Conus species identified (Davis et al. 2009). 
Figure 5. Distribution of the main chemical classes of natural products in the most 
important biological activities. 
An interesting feature of animal-derived products is the high proportion of 
compounds originating from marine sources, with more than half of the animal-derived 
NPs in the DNP belonging to sponges (i.e., Ceractinomorpha, Tetractinomorpha, and 
Homoscleromorpha) and cnidarians (i.e., Octocorallia and Hexacorallia) (Suppl. Mat. 
S1D). It is noteworthy that species from the Animalia kingdom are highly represented in 
aquatic environments, with 32 of the 33 animal phyla being marine (Cragg and Newman 
2013). Historically, the first discovery of biologically active compounds from a marine 
environment was that of the nucleosides spongouridine and spongothymidine, isolated 
from the Caribbean sponge, Tectitethya crypta in the early 1950s (Dias et al. 2012). Two 
decades later, the systematic investigation of bioactive products from marine sources 
began thanks to the development of scuba diving techniques as well as the use of 
submersibles (Cragg and Newman 2013). 
With 8,656 compounds in the DNP, the Porifera phylum (sponges) is by far the 
most represented amongst the Animalia kingdom. This phylum, comprising about 8,500 
species, has also been reported to be the most prolific marine producer of natural 
compounds (approximately 30% of all NPs from marine sources) with an average of 200 
compounds described each year (Van Soest et al. 2012; Blunt et al. 2015, 2017).%In the 
DNP, Dysidea is the genus with the highest number of NPs from the Porifera phylum, 
while Theonella swinhoei (also from the Porifera phylum) is the largest producer of NPs 
from the Animalia kingdom. In a review of marine sponge-derived NPs, Mehbub et al. 
(2014) suggested that the high number of NPs found in key orders of the sponges 
including Dictyoceratida (including Dysidea spp.), Haplosclerida, Halichondrida, 
Poecilosclerida, and Astrophorida was the result of high species diversity in these orders. 
Another reason could be the diversity and host specificity of microbial symbionts found in 
these species, which are responsible for the synthesis of some of the metabolites isolated 
from these sponges (Thomas et al. 2010). This is the case for Dysidea spp. which host a 
distinct cyanobacterial clade that may be responsible for the variable patterns in 
secondary metabolites found in this genus (Thacker and Starnes 2003). More generally, 
terpenoids, alkaloids, as well as peptides represent the main chemical classes of 
compounds found in the Porifera phylum, and more than half of the biological activities 
investigated were anticancer properties (Mehbub et al. 2014). Three compounds derived 
from marine sponges have been approved by the FDA including the anti-tumour 
compound eribulin mesylate, which is an analogue of halichondrin B first isolated from 
Halichondria okadai (Agrawal et al. 2016). 
According to the DNP Cnidarians are the second-largest producer of NPs from 
animal sources (5,249 NPs). This group of relatively simple animals comprises over 
11,000 species, and includes reef-forming corals, sea anemones, soft corals, jellyfishes, 
and marine hydroids (Daly et al. 2007; Appeltans et al. 2012). The Cnidarian phylum 
contains the Sinularia genus which, according to the DNP, is by far the biggest producer 
of NPs from the Animalia kingdom, while Clavularia viridis is the most prolific Cnidarian 
species. Both taxa belong to the Alcyonacea order (soft corals) which have been 
described as the main source of NPs from Cnidarians (Leal et al. 2012). With more than 
160 known species, Sinularia are one of the richest genera from the Alcyonacea order 
(Roskov et al. 2018). They produce a wide range of secondary metabolites including 
sesquiterpenes, polyhydroxylated steroids, polyamine compounds, as well as 
cembranoid diterpenes which are the most frequently isolated NPs from Sinularia (Chen 
et al. 2012). Some of these compounds display various bioactivities such as antiulcer 
properties (e.g., sinulide), anti-inflammatory activities (e.g., gibberoketosterol) and anti-
tumour activities (e.g., flexilarin D) (Rocha et al. 2011). Altogether, most of the bioactive 
compounds found in Cnidarians belong to the terpenoids (i.e., monoterpenoids, 
diterpenoids, and sesquiterpenoids).%Most of the interest in NPs isolated from Cnidarians 
surrounds their potential anti-tumour and anti-inflammatory activities (Rocha et al. 2015). 
To date, none of the compounds isolated from Cnidarians have been developed as drugs, 
however some compounds have been exhaustively investigated in preclinical studies, 
such as the diterpene glycoside pseudopterosin extracted from the sea whip 
Pseudopterogorgia elisabethae; eleutherobin derived from the soft coral Eleutherobia sp; 
and the diterpene sarcodictyn, found in some corals (Mariottini and Grice 2016). In 
addition, more than 70 compounds extracted from Cnidarians have been reported to 
possess promising bioactivities and thus might be of interest for future clinical studies 
(Rocha et al. 2011). 
Targeting the most prolific biological organisms: popular taxa vs unexplored phyla 
Targeting “popular” taxonomic groups seems to be a common way to uncover new 
natural compounds.% In the DNP, a large number of NPs originate from species-rich 
biological groups. As an example, in the Plantae kingdom the highest number of natural 
compounds can be isolated from the Compositae and Leguminosae families, and they 
are also amongst the three largest botanical families in the world. In the Animalia 
kingdom, a high proportion of compounds originate from marine sources, but 32 of the 33 
phyla in the Animalia kingdom include species from aquatic environments. Thus, the 
accessibility of biological sources (i.e., wide abundance and distribution) probably plays 
an important role in the selection of candidate species for further investigation. This is 
especially true for some marine taxa, for which the abundance, size, and colour have 
been reported to influence the selection process (Blunt et al. 2008). Indeed, “popular” 
taxa provide a wide range of NPs with high chemical diversity, thus suggesting the 
potential of these taxa as sources for drug discovery (Leal et al. 2012). The popularity of 
some organisms might also be related to their high-yield of bioactive compounds. For 
instance, Streptomyces spp., the most investigated genus in our analysis, exhibited the 
highest yield of bioactive compounds. Although it has been widely investigated, 
Streptomyces spp. continue to deliver novel scaffolds, such as the antibiotic 
platensimycin launched in 2006, as well as many other compounds currently under 
investigation in clinical trials (de Lima Procópio et al. 2012; Genilloud 2017). Furthermore, 
an increasing number of compounds thought to originate from plants or animals can now 
be reattributed to microbial organisms (e.g., endophytes, symbionts). Therefore, the high 
number of compounds found in one particular taxonomic group could in fact be produced 
by microbial sources. As an example, 31 of the 32 polyketide metabolites isolated from 
the sponge Theonella swinhoei, the most represented species from the Animalia kingdom 
in our study, have been reattributed to an uncultured bacterium (Wilson et al. 2014).  
While some researchers will prefer to focus on “popular” taxonomic groups 
exhibiting high chemical diversity, others will select unexplored phyla or geographical 
regions (Leal et al. 2012). Estimates for the total number of non-microbial species living 
on Earth range from 2 to 100 million (May 2010). However, some authors suggested that 
this number might be narrower and range between 5 and 10 million (Mora et al. 2011; 
Costello et al. 2013). If we compare the number of species catalogued with those 
predicted, the most interesting groups with a large number of species still to be discovered 
are likely to be fungi (≈ 100,000 species catalogued vs 0.8-5 million predicted) and 
animals (1-2 million vs 5-10 million) (Scheffers et al. 2012; Pimm et al. 2014). In contrast, 
more than two thirds of the predicted number of plant species (≈450,000) are already 
known (Pimm and Joppa 2015). Regarding bacteria, the total number of species is quite 
difficult to evaluate and estimates range between 103 to 1012 species (Pedrós-Alió 2006; 
Locey and Lennon 2016). In addition, some authors argued that marine environments 
and biodiversity hotspots could be a great source of new taxa (Mora et al. 2011; Scheffers 
et al. 2012). Species from specific taxonomic groups and geographical regions could be 
a source of NPs with potential bioactivity. In a recent paper, Pye et al. (2017) 
demonstrated that identifying new biological organisms leads to a burst in the discovery 
of structurally novel compounds, while investigating already studied classes of organisms 
is likely to yield existing classes of compounds. Therefore, further studies should be 
performed to identify biological organisms with great potential. This could be done by 
mapping the distribution area of un-investigated (or less investigated) phyla,%based on a 
datamining-guided search of an exhaustive as possible NP database. 
NP research in the pharmaceutical industry 
Historically, NPs have formed the basis of the therapeutic arsenal developed by 
pharmaceutical companies, and today they still represent a huge reservoir of inspirational 
bioactive chemodiversity. Out of the 293,798 NPs compiled in the DNP database, only 
3,882 (≈1%) were reported to have biological activities, viz. compounds with established 
activity and being used as drugs or under investigation for drug use. This raises concerns 
about the future potential of NPs as drug candidates.  
Historical background 
Plants and NPs have historically been valuable sources of effective medicine. In 
the beginning of the nineteenth century, pure NPs started to be isolated from medicinal 
plants and administered as pure and unique active principles at precise dosages. This 
was the beginning of the single and “magic bullet” paradigm (Strebhardt and Ullrich 2008). 
In the meantime, herbalism with its mixture of multi-active NPs lost credit. Natural 
products then reached their moment of glory when hundreds of pharmaceutical 
companies were trying to associate clinical activity with the presence of a particular NP 
(Figure 6, phase 1800 to 1980). Inspired by the seminal huge screening campaigns 
initiated in 1938 by Jonathan Hartwell and the Cancer program at the National Cancer 
Institute in 1955, many companies ran large-scale drug discovery screening programs.%
The pharmaceutical industry turned towards the thousands of NPs found in genetic 
resources for their high throughput screening (HTS) drug discovery programs, made 
possible with the advent of miniaturization and robotics. During this phase (1980-2005), 
drug discovery strategies made a 180-degree turn, starting with target molecules (e.g., 
enzymes, receptors, and ion channels) and moving up to cells, groups of cells, tissues, 
animals, and finally human patients. High throughput screening and molecular assays 
were performed in more and more dense microtiter plates (96, 384 or 1536 wells) at the 
farthest distance from the patient to conduct more and more experiments (up to 100,000 
wells tested per day). Despite huge throughputs, and the advantage of screening very 
large numbers of compounds at a time,%high attrition rates were observed when moving 
from hits active on a biological molecule towards the complexity of a human being. A HTS 
hit can easily access the target molecule in solution, but this is more difficult with cells, 
tissues, and complex biological organisms like laboratory animals (David and Ausseil 
2014).%Besides, by the end of the 1990s new techniques such as combinatorial chemistry, 
virtual screening, and even the deciphering of the human genome monopolized financial 
investments diverting funds away from NP screening programs.%The Human Genome 
Project was supposed to generate thousands of new druggable proteins as 
pharmacological targets. But in fact, the number of targets rose from 300 to around 600 
(Rask-Andersen et al. 2014). 
Figure 6. Evolution of the research strategies utilized by Pharma companies. 
Current state of NP research in Pharma companies 
Since the beginning of the twenty-first century, research into NPs has largely been 
downsized.%The probability of a hit from a HTS screening program reaching the market is 
around one in a million and the cost from hit to approval about $ 3 billion (Oprea 2000; 
DiMasi et al. 2016). 
Paradigms need to change as a single approach is no longer possible. In drug 
discovery hits at a molecular level need to be validated up to the patient level. Drug 
discovery needs to connect the patients’ scale to the scale of molecules by translational 
medicine. Moreover, computational and combinatorial chemistry techniques are now 
being combined and applied to drug discovery. 
Nowadays studies on traditional knowledge are restricted to academic research 
mostly on tropical diseases. But in the meantime, the economic and social demand for 
“green” food supplements, botanical drugs, and NP-based medicine is expanding. 
Main reasons for the decline in NP research 
It is clear that for decades (or even centuries) traditional medicines have been 
raided by pharmaceutical companies and turned into active molecules. Therefore, most 
of the easiest “low-hanging fruits” have been picked (David and Ausseil 2014). An 
analysis of new structures described in the commercial database AntiMarin (measured 
by the Tanimoto index) reveals that newly reported NPs are becoming more and more 
similar to structures already described (Pye et al. 2017). 
High throughput screening and even phenotypic high content screening on small 
animals have not been able to generate a return on investment with the introduction of 
new chemical entities on the market. In this strategy, researchers wait for an improbable 
“alignment of planets” between the druggability of NPs and the specific biological target 
screened. The number of potential targets is not boundless, even after the deciphering of 
the human genome (around 600 druggable targets). Even huge phenotypic screening 
campaigns on small animals were not able to optimize this passive “lottery” approach. 
This strategy was based on the premise that a large library of NPs should contain the 
perfect gem dedicated to the pharmacological target being studied. 
The complexity and inherent slowness of working with NPs was one of the reasons 
for the downsizing or shutdown of NP drug discovery programs. The supply, re-supply 
and authentication of genetic resources, as well as the isolation and identification of active 
molecules through bio-guided fractionation is not an easy game (Atanasov et al. 2015). 
The implementation of tedious access laws for genetic resources also had a negative 
effect on bioprospection and NP research, along with paradoxical effects on biodiversity 
conservation (David 2018).  
Trends for the future 
For the last two decades,%research efforts into NPs have gone phases of decline 
and renaissance. Nevertheless, NPs still represent a huge source of potential drug leads, 
but research strategies need to evolve with the times and new paradigms need to be 
invented.   
Since it was discontinued in the beginning of the 2000s, bioprospection will remain 
marginal in Big Pharma. Only Novartis and Pierre Fabre are still working on higher plants 
for drug discovery. The few companies involved in NP research are rather focusing on 
microorganisms or marine organisms which offer more “low-hanging fruits” in 
underexplored biotopes. More than 90% of microorganisms are not cultivable, but 
heterologous models make it possible to produce NPs from these organisms should allow 
the production of novel or “cryptic” NPs (Palazzolo et al. 2017). 
For scientific and administrative reasons, for two centuries pharmaceutical 
companies have focused their research efforts on the discovery of pure active 
compounds. This is the “magic bullet” paradigm. But plants act in more subtle ways. 
However, it should be admitted that the “single bullet” approach is not always the best 
approach, and indeed multitherapy is favoured in the treatment of AIDS and other 
infective diseases. Thus, in some chronic or metabolic diseases the single high affinity 
bullet should be replaced by a swarm of less active bullets as in phytotherapy and 
traditional African, Indian or Chinese medicines. The synergetic combination approach is 
gaining more and more interest. It is likely that paradigms will evolve away from single 
molecules to well-defined extracts simultaneously addressing multiple pharmacological 
targets,%as is the proposed mechanism of action for botanical drugs. 
Novel scientific methods for the discovery, validation, characterization, and 
standardization of these multicomponent botanical drugs will surely become more and 
more recognised by Health agencies. Products from vegetal origin such as Acheflan®, 
Angipars®, Epogam®, Fulyzaq®, Iberogast®, Picato®, Rosaderm® and Veregen® are 
paving the way towards the new paradigm. 
Meanwhile, the economic and social need for food supplements, phytotherapy, 
and botanical drugs is growing. The cultivation of medicinal plants for the production of 
standardized enhanced traditional medicines is recommended by the World Health 
Organization and was advocated in 2008 with the Beijing declaration (World Health 
Organization 2008). This makes sense in terms of cost, availability, and environmental 
impact. Pharmacological screening is generally conducted with a huge number of 
compounds on one specific biological target. But the opposite is possible with selectivity 
profiling, id est the screening of one NP on a lot of targets (Pouny et al. 2014). Re-
purposing old NPs which benefit from decades of pharmacovigilance is also a fruitful 
approach (Cragg et al. 2014). 
Fragment-based drug discovery looks very promising. This ground-breaking 
technique uses a restricted library of approximately 500 small natural molecules (150-250 
Da called “fragments”). Optimized libraries of natural fragments cover a larger chemical 
space than synthetic fragments and offer straightforward growing possibilities to cover a 
huge chemodiversity space (Pascolutti et al. 2015). 
Translational medicine, neural network analyses, and the generation of large data 
sets have started to allow molecular interactome studies, and links between biological 
systems to disease mechanisms are very encouraging (Capriotti et al. 2018). New trends 
in NP research include microbial genomics, synthetic biology, control of NP biosynthesis 
and bioinformatics.%Computational approaches that can analyse large amounts of data 
are rapidly developing in every field of NP research (Sarker and Nahar 2018). 
Limitations 
This study has several limitations which are mainly linked to the composition of the 
DNP. Indeed, numerous biases related to the collection, isolation, and identification of 
biota and their chemical constituents can be found in this database. First of all, taxonomic 
data stems usually from the first report, hence sources can sometimes be wrongly 
assigned. As an example, the genus Lyngbya has been completely revised during the 
last five years. However, most of the species cited in this work are well known and readily 
identifiable (e.g., Aspergillus terreus, Azadirachta indica, Helianthus annuus, Nicotiana 
tabacum, and Saccharomyces cerevisiae) and so we expect to have very few incidences 
of misinformation. Moreover, for most of the analyses we have intentionally limited our 
study to the family level or higher taxonomic rank. Another limitation is that some 
biological sources cited in this work (e.g., Bacillus subtilis, Escherichia coli, and 
Streptomyces spp.) are used as hosts for the production of drugs and small molecules. 
Therefore, compounds reported in our study as being produced by these species may not 
originate from these species. Given the restricted number of species used as hosts and 
the recent development of this technique for some species (i.e., Streptomyces spp.), this 
limitation does not significantly affect our results. In addition, not all compounds reported 
in the DNP to have biological activities (3,882 NPs in total) have been used as drugs. 
Therefore, for some compounds, preclinical and clinical data may be limited, and their 
biological activities need to be confirmed. Finally, this dictionary is not exhaustive, and 
our study cannot be taken as a descriptive study of all known NP.  
Despite these limitations, our results correlate with the findings of Bérdy (2005) 
who aimed to provide a summary of bioactive compounds from microbial sources, as well 
as those from Blunt et al. (2015), Mehbub et al. (2014), and Hu et al. (2011) who reviewed 
the NPs derived from marine sources. 
Conclusion 
This review aimed to characterize the global diversity of compounds isolated from 
natural sources. We based our analysis on the DNP which is one of the most 
comprehensive libraries of NPs, and one of the few to link chemical entities to their natural 
sources.  
Our study of the diversity of natural compounds shows that a high proportion of 
NPs are from plant origin, with terpenoids being the most represented chemical class 
(except in the Bacteria kingdom), and antibacterial as well as antineoplastic activities are 
the two main biological activities reported. Besides the importance of plant-derived 
compounds, we also highlight the large number of NP isolated from Streptomyces spp. 
as well as from the Ascomycota phylum and marine sources (i.e., sponges and soft 
corals).  
Although a large number of compounds have been isolated from natural sources, 
few are used as medicines today. More integrative and comprehensive approaches 
should unravel the limitations in drug discovery from NPs outlined in this review. Drug 
discovery from NPs is still in its infancy, and NPs remain relevant in modern drug 
discovery.  
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